Cue Biopharma (CUE) Non-Current Assets (2017 - 2025)
Cue Biopharma (CUE) posted Non-Current Assets of $5.2 million for Q4 2025, down 10.23% sequentially from $5.8 million in Q3 2025, and down 25.86% YoY from $7.1 million in Q4 2024.
Cue Biopharma (CUE) Non-Current Assets (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Non-Current Assets for 9 years, with the latest figure at $5.2 million in Q4 2025.
- Quarterly Non-Current Assets fell 25.86% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.2 million (down 15.71% YoY) and the FY2025 annual result came in at $5.2 million, down 25.86% from the prior year.
- Non-Current Assets retreated to $5.2 million in Q4 2025 per CUE's latest filing, from $5.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $15.7 million in Q2 2022 and troughed at $5.2 million in Q4 2025.
- A 5-year average of $10.5 million and a median of $10.0 million in 2021 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Non-Current Assets tumbled 33.97% in 2021, then surged 69.37% in 2022.
- Over 5 years, Non-Current Assets stood at $14.9 million in 2021, then fell by 5.6% to $14.1 million in 2022, then declined by 28.52% to $10.1 million in 2023, then tumbled by 30.0% to $7.1 million in 2024, then retreated by 25.86% to $5.2 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $5.2 million, $5.8 million, and $9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.23 Mn |
| Sep 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | 9.86 Mn |
| Mar 31, 2025 | 6.32 Mn |
| Dec 31, 2024 | 7.05 Mn |
| Sep 30, 2024 | 7.55 Mn |
| Jun 30, 2024 | 8.43 Mn |
| Mar 31, 2024 | 9.28 Mn |
| Dec 31, 2023 | 10.08 Mn |
| Sep 30, 2023 | 11.37 Mn |
| Jun 30, 2023 | 12.23 Mn |
| Mar 31, 2023 | 12.93 Mn |
| Dec 31, 2022 | 14.10 Mn |
| Sep 30, 2022 | 14.60 Mn |
| Jun 30, 2022 | 15.75 Mn |
| Mar 31, 2022 | 14.76 Mn |
| Dec 31, 2021 | 14.93 Mn |
| Sep 30, 2021 | 8.62 Mn |
| Jun 30, 2021 | 10.00 Mn |
| Mar 31, 2021 | 11.32 Mn |